PE20010751A1 - Quinolin-2-ona como inhibidores de las proteinas resistentes a multiples farmacos - Google Patents
Quinolin-2-ona como inhibidores de las proteinas resistentes a multiples farmacosInfo
- Publication number
- PE20010751A1 PE20010751A1 PE2000001073A PE0010732000A PE20010751A1 PE 20010751 A1 PE20010751 A1 PE 20010751A1 PE 2000001073 A PE2000001073 A PE 2000001073A PE 0010732000 A PE0010732000 A PE 0010732000A PE 20010751 A1 PE20010751 A1 PE 20010751A1
- Authority
- PE
- Peru
- Prior art keywords
- ona
- quinolin
- inhibitors
- multiple drugs
- proteins resistant
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIERE A QUINOLIN-2-ONA CONDENSADO, DONDE HET ES UN HETEROARILO DE 5 MIEMBROS CON N Y OTRO N, O, S, EL C NO CONDENSADO AL HETEROARILO ES OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C6, ARILO, HETEROCICLO, SR12, ENTRE OTROS; R ES (CH2)m-CHR1NHR2, O(CH2)2NHR2, (CH2)mCOR3, NHR2, (CH2)m-CHR1NR4R5; R` ES H, OH, O-ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON FENILO, CICLOALQUILO C3-C7; m Y m' SON 0-2; R1 ES H, ALQUILO C1-C6; R2 ES H, COR6, CH2R6, SO2R7, C(=S)NHR7; R3 ES H, OH, ALCOXI C1-C6, UN AMINOACIDO, NR4R5; R4 ES H, OH, ALCOXI C1-C6, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, (ALQUIL C1-C4)-FENILO, ENTRE OTROS; n ES 1-4; q ES 0-3; R6 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, ARILO, TERC BUTOXI, ENTRE OTROS; R6' ES ALQUILO C1-C6, CICLOALQUILO C3-C6, (CH2)q-HETEROCICLO, ENTRE OTROS; r ES 0-2; R7 ES ALQUILO C1-C6, FENILO, R8 ES H, CO2R1; R9, R10, R11 SON H, HALO, CO2R1, ENTRE OTROS; R12 ES ALQUILO C1-C6, (ALQUIL C1-C4)-FENILO, ALQUENILO C2-C6, ENTRE OTROS; SI R9 Y R10 SON H, R11 ES CLORO; HET NO ES OXAZOL SUSTITUIDO CON METILO. UNA COMPOSICION QUE COMPRENDE ADEMAS UN AGENTE ONCOLITICO COMO DOXORUBICINA, DAUNORUBICINA, EPIRUBICINA, VINCRISTINA, ETOPOSIDO. EL COMPUESTO I ES UN INHIBIDOR DE PROTEINAS RESISTENTES A MULTIPLES FARMACOS (MRP1), INHIBE AL NEOPLASMA RESISTENTE DE VEJIGA, HUESO, MAMA, TESTICULOS, TIROIDES, LEUCEMIA LINFOBLASTICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15817599P | 1999-10-07 | 1999-10-07 | |
| US16978499P | 1999-12-09 | 1999-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010751A1 true PE20010751A1 (es) | 2001-07-18 |
Family
ID=26854809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001073A PE20010751A1 (es) | 1999-10-07 | 2000-10-06 | Quinolin-2-ona como inhibidores de las proteinas resistentes a multiples farmacos |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6670373B1 (es) |
| EP (1) | EP1224189B1 (es) |
| AT (1) | ATE316531T1 (es) |
| AU (1) | AU7824900A (es) |
| DE (1) | DE60025744D1 (es) |
| PE (1) | PE20010751A1 (es) |
| WO (1) | WO2001027116A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7430257B1 (en) * | 1998-02-12 | 2008-09-30 | Lot 41 Acquisition Foundation, Llc | Multicarrier sub-layer for direct sequence channel and multiple-access coding |
| DE60205103T2 (de) * | 2001-04-09 | 2006-04-20 | Eli Lilly And Co., Indianapolis | Verbindungen und methoden zur hemmung von mrp1 |
| CN1281210C (zh) * | 2003-11-29 | 2006-10-25 | 胡汛 | 五味子乙素在制备治疗肿瘤药物中的应用 |
| WO2005118583A1 (en) * | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| US7485649B2 (en) * | 2005-01-06 | 2009-02-03 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| EP3915367A1 (en) | 2010-08-18 | 2021-12-01 | BioSplice Therapeutics, Inc. | Diketones and hydroxyketones as catenin signaling pathway activators |
| KR20200133826A (ko) | 2011-01-28 | 2020-11-30 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| JO3370B1 (ar) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| HRP20190142T1 (hr) | 2013-02-22 | 2019-03-22 | Samumed, Llc | Gama-diketoni kao aktivatori signalizacijskog puta wnt/beta-katenina |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| WO2015116852A1 (en) | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| BR112017003959B1 (pt) | 2014-08-20 | 2022-08-02 | Samumed, Llc | Uso de um composto de fórmula i ou um sal dermatologicamente aceitável do mesmo |
| MX2018002000A (es) | 2015-08-18 | 2018-06-19 | Regeneron Pharma | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. |
| EP3495351A1 (en) * | 2017-12-08 | 2019-06-12 | Solvay Sa | Oxidation of a pyrazolyl ketone compound to the corresponding carboxylic acid |
| MA53481A (fr) | 2018-08-29 | 2021-07-07 | Regeneron Pharma | Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde |
| SG11202107735SA (en) | 2019-01-31 | 2021-08-30 | Sanofi Biotechnology | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
| US12440561B2 (en) | 2019-04-24 | 2025-10-14 | Sanofi Biotechnology | Method of diagnosis and treatment of rheumatoid arthritis |
| BR112021024445A2 (pt) | 2019-06-04 | 2022-02-15 | Regeneron Pharma | Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182290A (en) | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain oxazoloquinolinones; a new class of GABA brain receptor ligands |
| US5717092A (en) | 1996-03-29 | 1998-02-10 | Vertex Pharmaceuticals Inc. | Compounds with improved multi-drug resistance activity |
| JP2002510625A (ja) * | 1998-04-08 | 2002-04-09 | イーライ・リリー・アンド・カンパニー | Ｍｒｐ１の阻害方法 |
-
2000
- 2000-09-22 DE DE60025744T patent/DE60025744D1/de not_active Expired - Lifetime
- 2000-09-22 AU AU78249/00A patent/AU7824900A/en not_active Abandoned
- 2000-09-22 US US10/088,721 patent/US6670373B1/en not_active Expired - Fee Related
- 2000-09-22 WO PCT/US2000/021980 patent/WO2001027116A2/en not_active Ceased
- 2000-09-22 EP EP00968314A patent/EP1224189B1/en not_active Expired - Lifetime
- 2000-09-22 AT AT00968314T patent/ATE316531T1/de not_active IP Right Cessation
- 2000-10-06 PE PE2000001073A patent/PE20010751A1/es not_active Application Discontinuation
-
2003
- 2003-10-03 US US10/678,891 patent/US20040077675A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU7824900A (en) | 2001-04-23 |
| EP1224189A2 (en) | 2002-07-24 |
| US6670373B1 (en) | 2003-12-30 |
| DE60025744D1 (de) | 2006-04-13 |
| US20040077675A1 (en) | 2004-04-22 |
| WO2001027116A2 (en) | 2001-04-19 |
| ATE316531T1 (de) | 2006-02-15 |
| EP1224189B1 (en) | 2006-01-25 |
| WO2001027116A3 (en) | 2001-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010751A1 (es) | Quinolin-2-ona como inhibidores de las proteinas resistentes a multiples farmacos | |
| ATE384061T1 (de) | Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren | |
| CY1110933T1 (el) | 5,7-διαμινοπυραζολο[4,3-d]πυριμιδινες με ανασταλτικη της pde-5 δραστικοτητα | |
| BRPI0418031A (pt) | inibidores de quinase fosfonato-substituìdos | |
| BRPI0411897A (pt) | pirroldihidroisoquinolinas como inibidores de pde10 | |
| DE60309848D1 (de) | Purinderivate als kinaseinhibitoren | |
| NO20065114L (no) | Inhibitorer av IAP | |
| EA200500017A1 (ru) | Новые соединения | |
| CY1108567T1 (el) | Αντιθρομβωτικες ενωσεις | |
| CY1109886T1 (el) | Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
| BRPI0413973A (pt) | compostos | |
| DE602004031372D1 (de) | Nachweis von staphylococcus | |
| PE20011085A1 (es) | Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos | |
| MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
| ATE438398T1 (de) | Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| EA200301317A1 (ru) | Производные аминохинолина и его применение в качестве лигандов аденозина a3 | |
| EA200600607A1 (ru) | Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы | |
| EA200500191A1 (ru) | Кристаллический 2,5-дион-3-(1-метил-1h-индол-3-ил)-4-[1-(пиридин-2-илметил)пиперидин-4-ил]-1h-индол-3-ил]-1h-пирролмоногидрохлорид | |
| BR0208812A (pt) | Derivados fenil heterociclil éter como inibidores de recaptação de serotonina | |
| CY1105039T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ | |
| DE60108089D1 (de) | Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel | |
| DE60041001D1 (de) | Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |